The design and development of LRRK2 inhibitors as novel therapeutics for Parkinson's disease
X Bai, J Zhu, Y Chen, H Sun - Future Medicinal Chemistry, 2024 - Taylor & Francis
Parkinson's disease (PD) is a common neurodegenerative disease affecting nearly 10
million people worldwide and placing a heavy medical burden on both society and families …
million people worldwide and placing a heavy medical burden on both society and families …
Targets to Search for New Pharmacological Treatment in Idiopathic Parkinson's Disease According to the Single-Neuron Degeneration Model
S Huenchuguala, J Segura-Aguilar - Biomolecules, 2024 - mdpi.com
One of the biggest problems in the treatment of idiopathic Parkinson's disease is the lack of
new drugs that slow its progression. L-Dopa remains the star drug in the treatment of this …
new drugs that slow its progression. L-Dopa remains the star drug in the treatment of this …
Practical Three-Component Regioselective Synthesis of Drug-Like 3-Aryl(or heteroaryl)-5,6-dihydrobenzo[h]cinnolines as Potential Non-Covalent Multi-Targeting …
H Mousavi, M Rimaz, B Zeynizadeh - ACS Chemical …, 2024 - ACS Publications
Neurodegenerative diseases (NDs) are one of the prominent health challenges facing
contemporary society, and many efforts have been made to overcome and (or) control it. In …
contemporary society, and many efforts have been made to overcome and (or) control it. In …